Essa Pharma Q2 2023 Earnings Report

Entered into a clinical trial support agreement with Janssen to supply Erleada® (apalutamide) and Zytiga® (abiraterone acetate) for an ESSA-sponsored Phase 1 study of EPI-7386 combination therapies; enrollment expected to begin in the second half of 2023.

Continued to enroll patients into the fourth cohort of the Phase 1 EPI-7386 combination study with Xtandi® (enzalutamide); Phase 1 completion expected in 3Q2023 followed by the initiation of the randomized Phase 2 part of the study.

The Phase 1b EPI-7386 monotherapy expansion study in mCRPC patients is ongoing.

Cash position is expected to be sufficient to fund current and planned operations through 2025.